Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
OncoSil Medical Ltd (AU:OSL)
ASX:OSL
RESEARCH TOOLSreports
Holding AU:OSL?
Track your performance easily
OSL Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week Range<AU$0.01 - AU$0.01
Previous CloseAU$0.01
Volume2.77M
Average Volume (3M)7.26M
Market Cap
AU$51.08M
Enterprise ValueAU$40.02M
Total Cash (Recent Filing)AU$11.37M
Total Debt (Recent Filing)AU$304.21K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Feb 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume4,932,591
30 Day Avg. Volume7,261,011
Standard Deviation0.22
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)36.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
OncoSil Medical Ltd News
PremiumCompany Announcements
OncoSil Medical Expands Investment Options
PremiumCompany Announcements
OncoSil Medical Shareholders Approve Key Resolution
PremiumCompany Announcements
OncoSil Medical Marks Milestone in Spanish Market
PremiumCompany Announcements
OncoSil’s Director Appointment Delayed, Progress Continues
PremiumCompany Announcements
OncoSil Medical’s Revenue Down, Losses Up in 2024
PremiumCompany Announcements
OncoSil Medical Schedules Key Shareholder Meeting
PremiumCompany Announcements
OncoSil Medical Sees Surge in Cancer Treatment Sales
PremiumCompany Announcements
OncoSil Device Marks Breakthrough in Cancer SurgeryOptions Prices
Currently, No data available
---
Ownership Overview
2.91%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
97.09% Public Companies and
Individual Investors
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
Currently, no data Available
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Feb 25, 2025 which is in 158 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Aug 22, 2024. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 3,784,024,000 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
---
OncoSil Medical Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
30.00%
12-Months-Change
Fundamentals
Return on Equity
-171.02%
Trailing 12-Months
Asset Growth
-44.58%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company focused on localized radiation treatments for patients with pancreatic and bile duct cancer. Its product includes OncoSil, a silicon and phosphorus (p32) beta emitter radiation therapy for the treatment of pancreatic cancer.
---
Technical Analysis
---